FHA
CYCN icon

Flagship Harbor Advisors’s Cyclerion Therapeutics CYCN Stock Holding History

Flagship Harbor Advisors’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2
Closed – – 793
2020
Q3 		$0 Hold
2
– – ﹤0.01% 1957
2020
Q2 		$0 Hold
2
– – ﹤0.01% 2032
2020
Q1 		$0 Hold
2
– – ﹤0.01% 1885
2019
Q4 		$0 Hold
2
– – ﹤0.01% 1889
2019
Q3 		$0 Hold
2
– – ﹤0.01% 1859
2019
Q2 		$0 Buy
+2
New +$566 ﹤0.01% 1874

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Flagship Harbor Advisors's CYCN Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 2 shares.

Flagship Harbor Advisors first reported a position in CYCN in Q2 2019 and held it in 6 quarters. The position peaked at $0 in Q3 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 2 Cyclerion Therapeutics shares in Q4 2020.
  • Flagship Harbor Advisors first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 6 quarters.
  • Flagship Harbor Advisors's Cyclerion Therapeutics position peaked at $0 in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.